vs
Orthofix Medical Inc.（OFIX）とUNITED COMMUNITY BANKS INC（UCB）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED COMMUNITY BANKS INCの直近四半期売上が大きい（$276.5M vs $219.9M、Orthofix Medical Inc.の約1.3倍）。UNITED COMMUNITY BANKS INCの純利益率が高く（30.5% vs -1.0%、差は31.5%）。UNITED COMMUNITY BANKS INCの前年同期比売上増加率が高い（11.6% vs 2.0%）。過去8四半期でOrthofix Medical Inc.の売上複合成長率が高い（8.0% vs 6.2%）
オーソフィックスメディカル社は世界的な整形外科医療機器メーカーで、脊椎インプラント、整形外科用外傷治療製品、骨成長刺激療法機器、再生医療製品の開発・製造・販売を事業としています。北米、欧州、アジア太平洋を中心に整形外科医や医療機関向けに製品を提供し、筋骨格系疾患患者の治療成績向上に取り組んでいます。
ユナイテッド・コミュニティ・バンクは米国の金融機関で、米国南東部有数の総合金融サービスプロバイダーである。総資産は277億米ドル、アラバマ、フロリダ、ジョージア、ノースカロライナ、サウスカロライナ、テネシーの6州に200の営業拠点を展開し、サウスカロライナ州に本社を置く銀行の中で総資産規模が最大である。
OFIX vs UCB — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $219.9M | $276.5M |
| 純利益 | $-2.2M | $84.3M |
| 粗利率 | 71.1% | — |
| 営業利益率 | 0.2% | — |
| 純利益率 | -1.0% | 30.5% |
| 売上前年比 | 2.0% | 11.6% |
| 純利益前年比 | 92.4% | 18.0% |
| EPS（希薄化後） | $-0.05 | $0.69 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $276.5M | ||
| Q4 25 | $219.9M | $278.4M | ||
| Q3 25 | $205.6M | $276.8M | ||
| Q2 25 | $203.1M | $260.2M | ||
| Q1 25 | $193.6M | $247.7M | ||
| Q4 24 | $215.7M | $250.9M | ||
| Q3 24 | $196.6M | $217.3M | ||
| Q2 24 | $198.6M | $245.3M |
| Q1 26 | — | $84.3M | ||
| Q4 25 | $-2.2M | $86.5M | ||
| Q3 25 | $-22.8M | $91.5M | ||
| Q2 25 | $-14.1M | $78.7M | ||
| Q1 25 | $-53.1M | $71.4M | ||
| Q4 24 | $-29.1M | $75.8M | ||
| Q3 24 | $-27.4M | $47.3M | ||
| Q2 24 | $-33.4M | $66.6M |
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 40.5% | ||
| Q3 25 | -8.3% | 42.6% | ||
| Q2 25 | -7.9% | 38.6% | ||
| Q1 25 | -25.2% | 36.8% | ||
| Q4 24 | -5.3% | 38.4% | ||
| Q3 24 | -9.6% | 27.5% | ||
| Q2 24 | -12.5% | 35.1% |
| Q1 26 | — | 30.5% | ||
| Q4 25 | -1.0% | 31.1% | ||
| Q3 25 | -11.1% | 33.0% | ||
| Q2 25 | -6.9% | 30.3% | ||
| Q1 25 | -27.4% | 28.8% | ||
| Q4 24 | -13.5% | 30.2% | ||
| Q3 24 | -13.9% | 21.8% | ||
| Q2 24 | -16.8% | 27.2% |
| Q1 26 | — | $0.69 | ||
| Q4 25 | $-0.05 | $0.71 | ||
| Q3 25 | $-0.57 | $0.70 | ||
| Q2 25 | $-0.36 | $0.63 | ||
| Q1 25 | $-1.35 | $0.58 | ||
| Q4 24 | $-0.76 | $0.61 | ||
| Q3 24 | $-0.71 | $0.38 | ||
| Q2 24 | $-0.88 | $0.54 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $82.0M | $493.1M |
| 総負債低いほど良い | — | $205.5M |
| 株主資本純資産 | $450.0M | $3.7B |
| 総資産 | $850.6M | $28.2M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.06× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $493.1M | ||
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — |
| Q1 26 | — | $205.5M | ||
| Q4 25 | — | $120.4M | ||
| Q3 25 | $157.2M | $155.3M | ||
| Q2 25 | $157.0M | $155.1M | ||
| Q1 25 | $156.9M | $254.3M | ||
| Q4 24 | $157.0M | $254.2M | ||
| Q3 24 | $118.5M | $316.4M | ||
| Q2 24 | $118.0M | $324.9M |
| Q1 26 | — | $3.7B | ||
| Q4 25 | $450.0M | $3.6B | ||
| Q3 25 | $442.5M | $3.6B | ||
| Q2 25 | $458.3M | $3.6B | ||
| Q1 25 | $458.3M | $3.5B | ||
| Q4 24 | $503.1M | $3.4B | ||
| Q3 24 | $525.9M | $3.4B | ||
| Q2 24 | $546.0M | $3.3B |
| Q1 26 | — | $28.2M | ||
| Q4 25 | $850.6M | $28.0B | ||
| Q3 25 | $832.6M | $28.1B | ||
| Q2 25 | $837.2M | $28.1B | ||
| Q1 25 | $823.1M | $27.9B | ||
| Q4 24 | $893.3M | $27.7B | ||
| Q3 24 | $867.9M | $27.4B | ||
| Q2 24 | $882.0M | $27.1B |
| Q1 26 | — | 0.06× | ||
| Q4 25 | — | 0.03× | ||
| Q3 25 | 0.36× | 0.04× | ||
| Q2 25 | 0.34× | 0.04× | ||
| Q1 25 | 0.34× | 0.07× | ||
| Q4 24 | 0.31× | 0.07× | ||
| Q3 24 | 0.23× | 0.09× | ||
| Q2 24 | 0.22× | 0.10× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $27.7M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $16.8M | — |
| FCFマージンFCF / 売上 | 7.6% | — |
| 設備投資強度設備投資 / 売上 | 4.9% | — |
| キャッシュ転換率営業CF / 純利益 | — | — |
| 直近12ヶ月FCF直近4四半期 | $-1.3M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $384.0M | ||
| Q3 25 | $12.4M | $123.1M | ||
| Q2 25 | $11.6M | $96.8M | ||
| Q1 25 | $-18.4M | $98.6M | ||
| Q4 24 | $23.7M | $349.7M | ||
| Q3 24 | $11.7M | $7.7M | ||
| Q2 24 | $9.0M | $105.1M |
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $356.5M | ||
| Q3 25 | $2.5M | $117.7M | ||
| Q2 25 | $4.5M | $84.7M | ||
| Q1 25 | $-25.1M | $94.3M | ||
| Q4 24 | $15.2M | $302.7M | ||
| Q3 24 | $6.3M | $-2.2M | ||
| Q2 24 | $-360.0K | $87.2M |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 128.0% | ||
| Q3 25 | 1.2% | 42.5% | ||
| Q2 25 | 2.2% | 32.6% | ||
| Q1 25 | -13.0% | 38.1% | ||
| Q4 24 | 7.0% | 120.7% | ||
| Q3 24 | 3.2% | -1.0% | ||
| Q2 24 | -0.2% | 35.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 9.9% | ||
| Q3 25 | 4.8% | 1.9% | ||
| Q2 25 | 3.5% | 4.7% | ||
| Q1 25 | 3.5% | 1.7% | ||
| Q4 24 | 4.0% | 18.8% | ||
| Q3 24 | 2.7% | 4.6% | ||
| Q2 24 | 4.7% | 7.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.44× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.23× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | — | 4.61× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 1.58× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
UCB
| Deposits | $98.0M | 35% |
| Investment securities, including tax exempt of $1,646 and $1,678, respectively | $45.3M | 16% |
| Money market | $40.7M | 15% |
| Time | $28.7M | 10% |
| NOW and interest-bearing demand | $28.1M | 10% |
| Service charges and fees | $9.5M | 3% |
| Other | $8.0M | 3% |
| Mortgage loan gains and other related fees | $8.0M | 3% |
| Wealth management fees | $4.6M | 2% |
| Lending and loan servicing fees | $4.0M | 1% |
| Deposits in banks and short-term investments | $1.2M | 0% |
| Securities gains, net | $133.0K | 0% |
